drugset / Trial / NCT00976443

Effects of Gastric Antral Botulinum Toxin Injections in Obese Subjects

NCT00976443

Phase 1 Completed 60 enrolled Mayo Clinic
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Obesity is an important public health problem in the United States. The investigators hypothesize that stomach injections of botulinum toxin A (BTA), delivered through an endoscope using endoscopic ultrasound (EUS), may cause delayed gastric emptying, satiation, and reduction in body weight. This protocol is designed to study the effects and safety of gastric BTA injections. Subjects are randomized to receive placebo or one of two different doses of BTA injected into the stomach during one endoscopy, performed via the mouth. Gastric emptying, satiation, symptoms, psychological dimensions of eating behavior, and caloric intake are recorded before and after injections, and subjects are seen in follow-up for 24 weeks.

Timeline

Start
2009-09
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 100 iu Other
Comparator Botulinum toxin type A Protein / enzyme biologic 300 iu Other

Indications